DECISION DIAGNOSTICS DEADLINE ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Decision Diagnostics Corp. (“Decision Diagnostics” or the “Company”) (Other OTC:DECN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $100,000 investing in Decision Diagnostics stock or options between March 3, 2020 and December 17, 2020 and would like to discuss your legal rights, please call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) or fill out the form below.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.
As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (2) the Company could not meet the FDA's emergency use authorization (“EUA”) testing requirements for its purported COVID-19 test; (3) accordingly, Defendants had misrepresented the timeline within which it could realistically bring its COVID-19 test to market; (4) all the foregoing subjected Defendants to an increased risk of regulatory oversight and enforcement; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Specifically, on December 17, 2020, the Securities and Exchange Commission (“SEC”) filed a complaint in federal court against Defendants, alleging that they had issued a series of press releases that falsely claimed that Decision Diagnostics had developed a finger-prick blood test that could detect COVID-19 in less than one minute (the "SEC Complaint"). According to the SEC Complaint, from March 2020 to at least June 2020, Defendants made false and misleading statements about the existence of Decision Diagnostics' COVID-19 device and progress towards achieving FDA EUA for that device. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. The SEC Complaint further alleged that the statements created the misleading impression that Decision Diagnostics would soon introduce the COVID-19 test to the market, which led to surges in the price and trading volume of the Company's stock.
Following the filing of the SEC Complaint, Decision Diagnostics' common share price fell $0.06 per share, or 60%, to close at $0.04 per share on December 18, 2020.
Decision Diagnostics Corp. (DECN)
* The submission of this form does not create an attorney-client relationship.
Filed on 01/18/2021
Ticker Other OTC:DECN
Lead Plaintiff Deadline 03/16/2021
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin email@example.com Phone (404) 847-0617 Fax (404) 506-9534
James M. Wilson, Jr. firstname.lastname@example.org Phone (212) 983-9330 Fax (212) 983-9331